|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
680000440[A73450101]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ݼ¿(2007.03.01)(ÇöÀç¾à°¡)
\869 ¿ø/1ݼ¿(2002.04.09)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Æ÷À塤À¯Åë´ÜÀ§ |
ÀÚ»çÆ÷Àå´ÜÀ§ |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾ : °áÇÙ±Õ
¡Û ÀûÀÀÁõ : °áÇÙ
|
| 1ÀÏ ÃÖ´ë Åõ¿©·® |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ : ½ÃŬ·Î¼¼¸°À¸·Î¼ 1ȸ 250mg(¿ª°¡)À» 1ÀÏ 2ȸ °æ±¸Åõ¿©ÇÑ´Ù.
1ÀÏ ¿ë·®ÀÌ 1g(¿ª°¡)À» ÃʰúÇØ¼´Â ¾È µÈ´Ù.
¿øÄ¢ÀûÀ¸·Î ´Ù¸¥ Ç×°áÇÙÁ¦¿Í º´¿ëÅõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
2) ¿ì¿ïÁõ, °£Áú ȯÀÚ, ÁßÁõ ºÒ¾È ȯÀÚ, Á¤½Åº´ ȯÀÚ(°£ÁúÀ¯»ç ¹ßÀÛ µîÀÇ Á¤½ÅÀå¾Ö¸¦ ¾ÇȽÃų ¼ö ÀÖ´Ù.)
3) ÁßÁõ ½ÅºÎÀü ȯÀÚ
4) ¾ËÄÚ¿ÃÀ» °ú·® ¼·ÃëÇÑ È¯ÀÚ
|
| ½ÅÁßÅõ¿© |
1) º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ Á¤½Åº´, °£ÁúÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ½ÅÀå¾Ö ȯÀÚ(Ç÷Áß³óµµ°¡ »ó½ÂÇϰí ÁßÃ߽Űæ°è µîÀÇ ÀÌ»ó¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.)
3) ¾ËÄÚ¿Ã Áßµ¶ÀÚ(¾ËÄÚ¿ÃÀÇ ÀÛ¿ëÀ» Áõ°½Ãų ¼ö ÀÖ´Ù.)
4) ¾Ë·¹¸£±â¼º ÇǺο°, È¥¶õ, °ú´Ù¹Ý»ç, µÎÅë, ¶³¸², ¾îÁö·¯¿ò, ºÒ¿ÏÀü¸¶ºñ, ¸»´õµëÁõ µîÀÇ ÁßÃ߽Űæ°è µ¶¼º Áõ»óÀ» ³ªÅ¸³»´Â ȯÀÚ
5) ÀÌ ¾àÀº Ȳ»ö5È£(¼±¼Â¿»·Î¿ì FCF, Sunset Yellow FCF)¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
1) Á¤½Å½Å°æ°è : µÎÅë, ¾îÁö·¯¿ò, Á¹À½, ¶³¸², ¿ì¿ï, Á¤½ÅÂø¶õ, ȯ°¢, È¥¼ö, Á¤½Åº´(ÀÚ»ì°æÇâ°¡Áü), °ú´Ù¹Ý»ç, °üÀýÅë, °æ·Ã, °£ÁúÀ¯»ç ¹ßÀÛ, ¸»ÃʽŰ濰, ºÒ¿ÏÀü¸¶ºñ, ¸»´õµëÁõ, ºÒ¸é, ¼º°Ýº¯È, °ú´ÙÈïºÐ, °ø°Ý¼º, °¨°¢ÀÌ»ó, ´ë․¼Ò°£´ë¼º¹ßÀÛ, ±â¾ï·Â »ó½ÇÀ» ¼ö¹ÝÇÑ Âø¶õ ¹× ¹æÇ⼺ »ó½ÇÀ» ¼ö¹ÝÇÑ Âø¶õ ¹× ¹æÇ⼺ »ó½Ç µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
2) ¼Òȱâ°è : ¶§¶§·Î ±¸¿ª, ½Ä¿åºÎÁø, º¹Åë, º¯ºñ, ¼³»ç µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼øÈ¯±â°è : 1ÀÏ 1¢¦1.5g Åõ¿© ½Ã °©ÀÛ½º·± ¿ïÇ÷¼º ½ÉºÎÀüÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
4) Ç÷¾×°è : ´Ù¸¥ °áÇÙ Ä¡·áÁ¦¿Í º´¿ëÅõ¿© ½Ã ºñŸ¹Î B12, ¿±»ê°áÇÌ, °Å´ëÀû¾Æ±¸¼º ºóÇ÷, öÀû¸ð±¸¼º ºóÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ºóÇ÷ÀÌ ³ªÅ¸³ª¸é ÃæºÐÈ÷ °üÂûÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
5) °ú¹Î¹ÝÀÀ : ÇǺιßÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ¾Ë·¹¸£±â¼º ÇǺο°ÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ±âŸ : Ç÷ûƮ·£½º¾Æ¹Ì³ªÁ¦ Áõ°¡°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù(ƯÈ÷ °£Áúȯ ȯÀÚ).
|
| »óÈ£ÀÛ¿ë |
1) ¿¡Ä¡¿Â¾Æ¹Ìµå¿Í º´¿ëÅõ¿© ½Ã ½Åµ¶¼º »ó½Â ¹× ½Å°æ°è ÀÌ»ó¹ÝÀÀÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
2) ¾ËÄÚ¿ÃÀº °£Áú¼º ¹ßÀÛ À§ÇèÀ» Áõ°¡½ÃŰ¹Ç·Î °¨·®ÇÏ´Â µî º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
3) À̼ҴϾÆÁöµå¿Í º´¿ëÅõ¿© ½Ã ¾îÁö·¯¿ò, Á¹À½ µî ÁßÃ߽Űæ°è¿¡ ´ëÇÑ ÀÌ»ó¹ÝÀÀÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(cycloserine. µ¿¹° ½ÇÇè¿¡¼ ÁߵÀÇ À§ÇèÀÌ º¸°íµÇ¾úÀ¸³ª, ÀӺΠ´ë»ó ÀÓ»ó½ÃÇèÀº Á¦ÇÑÀûÀÌ´Ù. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit. )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cycloserine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Cycloserine is an analog of the amino acid D-alanine. It interferes with an early step in bacterial cell wall synthesis in the cytoplasm by competitive inhibition of two enzymes, L-alanine racemase, which forms D-alanine from L-alanine, and D-alanylalanine synthetase, which incorporates D-alanine into the pentapeptide necessary for peptidoglycan formation and bacterial cell wall synthesis.
|
| Pharmacology |
Cycloserine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cycloserine, a broad-spectrum antibiotic, may be bactericidal or bacteriostatic, depending on its concentration at the site of infection and the susceptibility of the organism. Cycloserine works by blocking the formation of these peptidoglycans. By doing this the walls of the bacteria become weak and it results in the death of the bacteria
|
| Half-life |
Cycloserine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.
|
| Absorption |
Cycloserine¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly and almost completely absorbed (70 to 90%) from the gastrointestinal tract following oral administration.
|
| Toxicity |
Cycloserine¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral LD50 in mouse is 5290 mg/kg, and in rat is over 5000 mg/kg. Symptoms of a cycloserine overdose include drowsiness, confusion, headache, dizziness, irritability, numbness and tingling, difficulty speaking, paralysis, abnormal behavior, seizures, and unconsciousness.
|
| Drug Interactions |
Cycloserine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cycloserine¿¡ ´ëÇÑ Description Á¤º¸ Antibiotic substance produced by Streptomyces garyphalus. [PubChem]
|
| Dosage Form |
Cycloserine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Cycloserine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, UrinaryAntibioticsAntibiotics, AntitubercularAntimetabolites
|
| Smiles String Canonical |
Cycloserine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1CONC1=O
|
| Smiles String Isomeric |
Cycloserine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H]1CONC1=O
|
| InChI Identifier |
Cycloserine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/f/h5H
|
| Chemical IUPAC Name |
Cycloserine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4-amino-1,2-oxazolidin-3-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|